PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLevonordefrin
Levonordefrin
Carbocaine, Carbocaine W/ Neo-cobefrin, Ravocaine Novocain W/, Ravocaine Novocain W/ Neo-cobefrin, Scandonest L (levonordefrin) is a small molecule pharmaceutical. Levonordefrin was first approved as Carbocaine w/ neo-cobefrin on 1982-01-01. It is used to treat oral ulcer and toothache in the USA. It is known to target alpha-1D adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
stomatognathic diseasesD009057
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Norepinephrine bitartrate
+
Procaine hydrochloride
+
Propoxycaine hydrochloride
Tradename
Company
Number
Date
Products
RAVOCAINE AND NOVOCAIN W/ LEVOPHEDEastman KodakN-008592 DISCN1982-01-01
1 products
Hide discontinued
Levonordefrin
+
Procaine hydrochloride
+
Propoxycaine hydrochloride
Tradename
Company
Number
Date
Products
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRINEastman KodakN-008592 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
carbocaineANDA2024-02-21
carbocaine carbocaine with neo-cobefrinANDA2017-12-12
isocaine isocaine with levonordefrin2007-03-30
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
145 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnesthesiaD00075841115
Postoperative painD010149G89.1823813
PainD010146EFO_0003843R5215410
PulpitisD011671EFO_1001139K04.0113610
Local anesthesiaD00077222228
Knee osteoarthritisD020370EFO_0004616M1712226
Replacement arthroplasty kneeD019645415
Wounds and injuriesD014947T14.82125
Hip osteoarthritisD015207EFO_1000786M161134
Nerve blockD009407134
Show 36 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RuptureD012421123
Bone fracturesD050723EFO_0003931T14.8123
Forearm injuriesD005543S59.91112
Intervertebral disc degenerationD055959HP_00084191112
RadiculopathyD011843M54.1112
Job syndromeD007589EFO_0003775D82.411
Breast neoplasmsD001943EFO_0003869C5011
Wrist fracturesD00009250311
EmergenciesD00463011
AnalgesiaD00069811
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Low back painD017116HP_0003419M54.51134
Knee injuriesD007718112
Chronic periodontitisD055113EFO_0006343K05.3112
Covid-19D000086382122
Olfaction disordersD000857HP_0000458R43.0122
Peri-implantitisD057873EFO_100139011
Periodontal diseasesD010510K05.611
Back painD001416HP_0003418M54111
Spinal diseasesD013122M45-M49111
Ischemic strokeD00008324211
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577123
Healthy volunteers/patients22
Compartment syndromesD003161T79.A011
Acute painD059787R5211
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ganglion cystsD045888M67.433
Anterior cruciate ligament injuriesD00007059822
Hallux valgusD006215HP_000182222
BursitisD002062EFO_1000941M71.922
Tooth extractionD01408122
NeuralgiaD009437EFO_000943022
Postherpetic neuralgiaD05147422
Complex regional pain syndromesD020918EFO_100199822
Reflex sympathetic dystrophyD012019EFO_1001147G90.522
TendinopathyD052256EFO_1001434M77.922
Show 63 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLevonordefrin
INNcorbadrine
Description
Alpha-methylnoradrenaline is a catecholamine in which the 2-aminoethyl group is substituted with a hydroxy group at C-1 and a methyl group at C-2, with configurations 1R,2S. A metabolite of alpha-methyl-L-dopa, it is an alpha2-adrenergic agonist and acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. It has a role as an alpha-adrenergic agonist, a vasoconstrictor agent and a nasal decongestant.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H](N)[C@H](O)c1ccc(O)c(O)c1
Identifiers
PDB
CAS-ID829-74-3
RxCUI
ChEMBL IDCHEMBL677
ChEBI ID10304
PubChem CID164739
DrugBankDB06707
UNII IDV008L6478D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (Q61619)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 505 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
307 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use